Defibrillator Market: as claims data keeps confirming that guideline-eligible patients are not receiving implantable defibrillators at anywhere near the rate guidelines recommend, every corporate move that changes who owns the AED and ICD franchises now matters as much as any single device's technical performance, so competitive position is being reshaped by portfolio divestiture and acquisition as much as by clinical differentiation, and advantage is moving toward companies that can close the guideline-to-implant gap rather than those that simply defend share among already-treated patients.

The global defibrillator market size was USD 9.42 Billion in 2025 and is expected to register a revenue CAGR of 6.5% during the forecast period. Market revenue growth is driven by factors such as rising documented sudden cardiac arrest incidence, expanding public access defibrillation mandates, and next-generation implantable device clearances that reduce complication risk relative to transvenous systems. The first driving factor is the scale of sudden cardiac arrest incidence documented across major health systems. Implantable cardioverter-defibrillators account for approximately 44% of total 2025 market revenue, reflecting the clinical centrality of implantable rhythm management to overall defibrillator demand. The second driving factor is expanding public access defibrillation mandates that require AED placement in public venues, schools, and workplaces. The third driving factor is next-generation implantable device clearances, including extravascular and subcutaneous systems that avoid transvenous lead complications. These are some of the key factors driving revenue growth of the market.

A second layer of demand comes from the way portfolio-level corporate transactions reshape which company's commercial and clinical infrastructure a given AED or ICD franchise sits inside, which converts a single divestiture or acquisition into a broader shift in go-to-market resourcing across an entire product line without any change to the underlying device technology itself. Once an AED or ICD franchise changes ownership, the acquiring company's existing distribution relationships, regulatory affairs infrastructure, and clinical education investment extend to the acquired franchise, so the franchise's addressable market can expand or contract based on its new owner's commercial reach rather than on any change to the device itself. As a result, competitive share in this market is shaped as much by which company currently owns a given franchise as by the franchise's underlying clinical performance, and the forecast reflects this by weighting recent ownership transitions as a distinct driver of near-term market structure. For instance, in January 2025, Philips agreed to sell its Emergency Care business, including its HeartStart AED franchise, to investment firm Bridgefield Capital under a long-term exclusive brand licence arrangement, moving one of the market's most recognised AED brands to a new commercial owner. These are some of the key factors driving revenue growth of the market.

Because US Medicare claims data and European cardiac device registry analyses have both documented that a substantial share of patients who meet clinical guideline criteria for ICD implantation never receive one, the addressable market implied by clinical guidelines is structurally larger than the market these devices actually capture, and closing that gap depends on referral pathway and reimbursement barriers that are outside any single device maker's direct control.

AED maintenance and readiness gaps are a second constraint, because publicly placed AEDs require ongoing battery and pad replacement to remain functional in an actual emergency, and documented rates of non-functional public AEDs at the moment of use reduce the effective public health value of placement mandates even where device volume continues to grow.

Reimbursement variability across health systems is a third constraint, since ICD and CRT-D implantation reimbursement rates and prior authorisation requirements vary substantially by payer and country, which creates inconsistent patient access even where clinical guidelines are internationally aligned.

These factors substantially limit defibrillator market growth over the forecast period.

The clearest driver of demand is the scale of sudden cardiac arrest incidence documented across major health systems, combined with evidence that guideline-eligible patients are not receiving implantable defibrillators at the rate clinical guidelines recommend. Sudden cardiac arrest is fatal within minutes without defibrillation, so clinical guidelines define specific left ventricular ejection fraction and arrhythmia risk thresholds at which prophylactic ICD implantation is recommended, and any gap between that guideline-eligible population and actual implantation rates represents unmet clinical need that does not depend on any new technology to address. Implantable cardioverter-defibrillators account for approximately 44% of total 2025 market revenue, and both US Medicare claims data and European cardiac device registry analyses have documented meaningful underutilisation of ICDs in guideline-eligible populations. The effect on the market is that closing the guideline-to-implantation gap represents a larger addressable growth opportunity than technology innovation alone within the currently treated population. These are some of the key factors driving revenue growth of the market.

The second driver is the continued clinical adoption of extravascular and subcutaneous implantable defibrillator systems that avoid placing a lead directly in the heart or venous system. Traditional transvenous ICD leads carry a meaningful long-term risk of lead fracture, infection, and extraction complications, so a defibrillation system that can deliver the same life-saving therapy without a transvenous lead directly addresses the complication risk that has historically made some patients and physicians hesitant about early or prophylactic implantation. Boston Scientific received FDA approval for a next-generation subcutaneous ICD with a meaningfully smaller form factor, wireless connectivity, and real-time monitoring capability, extending the lead-free implantable defibrillator category beyond its first-generation design. The effect on the market is that lead-free implantable defibrillator adoption is expanding the pool of patients and physicians willing to consider earlier or prophylactic implantation. These are some of the key factors driving revenue growth of the market.

Implantable cardioverter-defibrillators already account for approximately 44% of 2025 defibrillator market revenue. Closing the documented gap between guideline eligibility and actual implantation represents the market's largest untapped growth pool.

The third driver is corporate portfolio restructuring activity among the largest defibrillator and cardiovascular device manufacturers, which is reshaping the commercial infrastructure behind major franchises. A company's decision to divest or acquire a device franchise changes which organisation's sales force, regulatory affairs team, and clinical education budget supports that franchise going forward, so restructuring activity can expand or contract a franchise's effective market reach independent of the underlying device technology. In January 2025, Philips agreed to sell its Emergency Care business, including its HeartStart AED franchise, to Bridgefield Capital under a long-term exclusive brand licence arrangement, and separately, Boston Scientific completed its acquisition of the remaining shares of Bolt Medical in April 2025, expanding its broader cardiovascular portfolio alongside its existing defibrillator business. The effect on the market is that near-term competitive positioning in both the AED and broader cardiovascular device categories is being shaped by ownership transitions as much as by product-level innovation. These are some of the key factors driving revenue growth of the market.

However, the defibrillator market faces severe adoption constraints from documented underutilisation of implantable defibrillators in guideline-eligible patient populations.

Because US Medicare claims data and European cardiac device registry analyses have both documented that a substantial share of patients who meet clinical guideline criteria for ICD implantation never receive one, the addressable market implied by clinical guidelines is structurally larger than the market these devices actually capture, and closing that gap depends on referral pathway and reimbursement barriers that sit largely outside any single device maker's direct control.

AED maintenance and readiness gaps compound this, because publicly placed AEDs require ongoing battery and pad replacement to remain functional in an actual emergency, and documented rates of non-functional public AEDs at the moment of use reduce the effective public health value of placement mandates even where device volume continues to grow steadily.

Reimbursement variability across health systems is the third constraint, since ICD and CRT-D implantation reimbursement rates and prior authorisation requirements vary substantially by payer and country, which creates inconsistent patient access even where clinical guidelines are internationally aligned on implantation criteria.

These factors substantially limit defibrillator market growth over the forecast period.

Based on product type, the global defibrillator market is segmented into automated external defibrillators, implantable cardioverter-defibrillators, CRT-D, and wearable cardioverter-defibrillators. Implantable cardioverter-defibrillators hold the largest revenue share, because they address the highest-acuity, guideline-driven patient population and carry substantially higher per-unit pricing than external devices, which suits a market where clinical severity, not unit volume, drives the largest revenue category. Automated external defibrillators remain established for public access and emergency response settings and are far cheaper per unit than implantable systems, but they cannot address the underlying arrhythmia risk that implantable systems continuously monitor and treat. Wearable cardioverter-defibrillators are expected to register the fastest revenue growth rate in the global defibrillator market over the forecast period, driven by their role as a bridge therapy for patients awaiting implant eligibility determination or recovering from a cardiac event, which is why manufacturers continue to expand wearable defibrillator indications.

Based on technology, the global defibrillator market is segmented into biphasic defibrillators, monophasic defibrillators, and semi-automatic and fully automatic AED. Biphasic technology holds the largest revenue share, because it is now the clinical standard across nearly all new implantable and external defibrillator systems, which suits a market where biphasic waveform delivery has become the default rather than a premium feature. Fully automatic AED technology is expected to register the fastest revenue growth rate in the global defibrillator market over the forecast period, driven by public access defibrillation programmes prioritising devices that require minimal bystander training, which is why AED manufacturers continue to prioritise fully automatic designs for public venue placement.

Based on end-use, the global defibrillator market is segmented into hospitals and cardiac catheterisation labs, emergency medical services, public access defibrillation, and home and ambulatory care. Hospitals and cardiac catheterisation labs hold the largest revenue share, because implantable device implantation and programming both occur in this setting, which ties directly back to the ICD-dominated product mix described in the market's primary demand driver. Public access defibrillation is expected to register the fastest revenue growth rate in the global defibrillator market over the forecast period, driven by expanding legislative mandates requiring AED placement in schools, workplaces, and public venues, which is why AED manufacturers continue to prioritise public venue-focused product design and pricing.

Based on regional analysis, the defibrillator market in North America accounted for largest revenue share in 2025. The United States leads because Medicare and commercial payer reimbursement infrastructure for ICD and CRT-D implantation is well established, and because Medtronic, Boston Scientific, and Abbott all maintain their primary commercial and regulatory presence in the US market. The documentation of ICD underutilisation specifically through US Medicare claims data reflects both the scale of the US guideline-eligible population and the depth of the claims infrastructure available to measure the gap. The concentration of FDA clearance activity in the country also means new implantable defibrillator technologies are typically launched in the United States first, before expanding to other regulatory jurisdictions.

The market in Europe is expected to register a steady revenue growth rate over the forecast period. Germany, the United Kingdom, and France represent the three largest national markets within Europe. Biotronik, headquartered in Germany, maintains its primary global commercial base in Europe, and European cardiac device registries provide some of the most detailed guideline-eligibility underutilisation data available globally. The result is steady rather than rapid growth, shaped more by national health system reimbursement negotiation than by underlying patient demand.

The market in Asia Pacific is expected to register a rapid revenue growth rate over the forecast period. China and Japan represent the two largest national markets within the region, driven by rising cardiovascular disease incidence and expanding hospital cardiac catheterisation lab infrastructure. Japan is the earlier-launch market for advanced implantable defibrillator technology in the region, which leaves more room for growth than in the already implant-saturated North American market.

The market in Latin America is expected to register a moderate revenue growth rate over the forecast period. Brazil and Mexico represent the two largest national markets within the region, with private hospital networks driving early implantable defibrillator adoption among higher-income patients. The ongoing Iran-US sanctions and the resulting Strait of Hormuz shipping disruption have raised freight and import costs for the specialised battery and electronic components that Latin American device distributors depend on, an effect expected to run through 2026 and slow defibrillator adoption beyond Brazil's and Mexico's main urban centres.

The market in Middle East and Africa is expected to register a moderate revenue growth rate over the forecast period. Saudi Arabia and the UAE represent the primary commercial markets within the region. Saudi Arabia's expanding private hospital network and the UAE's regional distribution hubs represent the primary investment centres for defibrillator adoption. Saudi Arabia is the most established market on the continent, while the Gulf states outside it are still building the cardiology infrastructure needed to support advanced implantable defibrillator systems at scale.